Human papillomavirus (HPV) is the major cause of uterine cervical cancer, but the role of the HPV E5 in carcinogenesis is not clearly understood. Prostaglandins are known to contribute to carcinogenesis of cervical cancer, and we therefore investigated the effect of HPV16 E5 on the expression of prostaglandin E2 (PGE2) receptors and underlying mechanisms. Stable expression of the E5 induced expression of the EP4 subtype of PGE2 receptors in C33A cervical cancer cells, and transfection of E5 small interfering RNA (siRNA) decreased it. EP4 protein expression was increased in human cervical cancer tissues, and EP4 mediated E5-induced increase in anchorage-independent colony formation and vascular endothelial growth factor expression. E5 induced cyclooxygenase-2 (COX-2) expression, and COX-2 increased PGE2 secretion and EP4 expression. The induction of EP4 by PGE2 and E5 was inhibited by an EP4 antagonist, inhibitors of cyclic adenosine monophosphate-dependent protein kinase or phosphatidylinositol 3-kinase, and a cyclic adenosine monophosphate response element (CRE) decoy. E5 increased the luciferase expression controlled by a variant CRE of the EP4 promoter, and it also increased the binding of cyclic adenosine monophosphate response element binding protein (CREB) to oligonucleotides containing this CRE. We conclude that the HPV16 E5 protein induces EP4 receptor protein in cervical cancer cells and that this induction involves epidermal growth factor receptor, COX-2, PGE2, EP2 and EP4, protein kinase A, CREB and CRE.
Introduction
Human papillomavirus (HPV) infection is the major cause of human uterine cervical cancer, and high-risk HPV types, including HPV16, encode three oncoproteins: E5, E6 and E7 (1, 2) . E6 proteins induce rapid degradation of p53 to prevent the host cell from inducing apoptosis, and E7 proteins inactivate pRb to force the host cell to continue cell division. However, the role of the E5 protein in cervical carcinogenesis is not clearly understood. The HPV16 E5 (E5) protein is a hydrophobic protein composed of 83 amino acids, and it is observed in the endoplasmic reticulum, Golgi apparatus and nuclear membrane of infected cells. The gene for E5 protein is considered an oncogene because it can transform cells in culture as well as increase tumorigenicity in nude mice (3) . E5 also induced skin tumors by contributing to two stages of skin carcinogenesis in transgenic mice (4, 5) . E5 has been shown to increase the level of epidermal growth factor receptor (EGFR) by delaying the internalization and degradation, and this has been suggested as one oncogenic mechanism (6) .
Prostaglandins are potent bioactive lipid messengers derived from arachidonic acid, and they are involved in a variety of physiological responses and diseases including inflammation and cancer. Prostaglandin E2 (PGE2) plays multiple functions by activating four G proteincoupled receptor subtypes (EP1, EP2, EP3 and EP4), which differ in their PGE2 binding affinities and downstream signal transduction pathways. EP2 and EP4 activate stimulatory G proteins to increase cyclic adenosine monophosphate (cAMP) synthesis by adenylate cyclases. Activation of EP1 increases Ca 2þ and inositol 1,4,5-trisphosphate levels, whereas EP3 inhibits cAMP synthesis (7) . EP receptors have been suggested to promote carcinogenesis of various tissues, including the cervix (8, 9) .
Therefore, we hypothesized that HPV16 E5 upregulates the activity of PGE2-signaling pathways by inducing PGE2 receptor expression to promote carcinogenesis. This study was designed to examine the effect of E5 on the expression of PGE2 receptors and the mechanisms underlying these effects. Our results show that the E5 protein induces EP4 through pathways involving EGFR, cyclooxygenase-2 (COX-2), PGE2, EP2, EP4, cyclic AMP-dependent protein kinase A (PKA), cyclic adenosine monophosphate response element binding protein (CREB) and cyclic adenosine monophosphate response element (CRE).
Materials and methods

Cell culture and reagents
Human cervical cancer cells were grown either in RPMI 1640 (C33A cells and CaSki cells; American Type Culture Collection, Manassas, VA) or in Dulbecco's modified Eagle's medium (HeLa cells; American Type Culture Collection). Both media contained 10% fetal bovine serum (JBI, Korea) and 100 U/ml penicillin/streptomycin. Cells were cultured in a CO 2 incubator at 37°C. PGE2, AH6809, AH23848, H89 and wortmannin were purchased form Sigma Chemical Co. (St Louis, MO) and forskolin, AG1478 and NS-398 from Calbiochem (Nottingham, UK). The nucleotide sequences of the decoy oligonucleotide for the CRE and those of the CRE mismatch control were 5#-TGACGTCATGACGTCATGACGTCA-3# and 5#-CTAGCTAGCTAGC-TAGCTAGCTAG-3#, respectively.
Stable expression of E5 and COX-2 HPV16 E5 and human COX-2 complementary DNA (a gift of Dr Stephen M. Prescott, Oklahoma Medical Research Foundation, Oklahoma City, OK) (10) were stably expressed in HPV-negative C33A cervical cancer cells using expression constructs in pcDNA3 vector (InVitrogen, Paisley, UK). FLAGtagged E5 was constructed by polymerase chain reaction (PCR) using the HPV16 E5 as template and primers with BamHI or XhoI restriction sites (the sequence of the FLAG epitope tag is underlined): 5#-GGGGATCCAC-CATGGGACTACAAAGACGATGACGACAAGTACTGCATCCACAACAT-TACT-3# and 5#-CGCTCGAGTTATGTAATTAAAAAGCGTGC-3#. The resulting PCR product was ligated with the pcDNA3 plasmid using BamHI and XhoI sites, and the inserted sequences were confirmed by DNA sequencing. Subconfluent cells were transfected with 10 lg of respective plasmid DNAs using Lipofectamine (Invitrogen, Carlsbad, CA). Transfected cells were selected by growing cells in the presence of 250 lg/ml G418 (Calbiochem), and the selected cells were screened for E5 or COX-2 expression.
RNA interference
Synthetic HPV16 E5 small interfering RNAs (siRNAs) (Qiagen, Valencia, CA) were transfected with Lipofectamine, and total RNA and protein were extracted at 48 h after transfection for analysis. The control and E5 siRNA sequences were 5#-AATTCTCCGAACGTGTCACGT-3# and 5#-TGGTAT-TACTATTGTGGATAA-3#, respectively.
Immunoblot analysis
The expression of proteins was analyzed by western blotting using specific antibodies. The antibodies used were specific to the FLAG epitope (Sigma Chemical Co.), COX-2, b-actin (Santa Cruz Biotechnology, CA) and EP4 (Cayman Chemicals, MI). The densities of visualized bands were quantified using the Multi Gauge v2.3 software (Fuji, Tokyo, Japan), and protein amount was expressed as a percentage or a multiple of corresponding densities of the control.
Immunohistochemical analysis of EP4 expression in cervical cancer tissues Surgically resected cervical cancer tissue specimens were obtained and collected from patients who underwent hysterectomy at Seoul National University Hospital. The clinicopathological parameters such as age, histological subtype, the presence of lymph node or distant metastasis and pathological stage were evaluated by reviewing the medical charts and pathological records. The collected 52 cervical cancer tissues were composed of 48 squamous cell carcinoma tissues, 2 adenocarcinoma tissues and 2 adenosquamous carcinoma tissues. The mean patient age was 51.0 years. This study was approved by the Institutional Review Boards of Seoul National University Hospital. Using the cancer tissues, tissue array and immunohistochemical analysis were performed using established techniques described previously (12) . Immunohistochemical staining against EP4 was done using a streptavidin peroxidase procedure following microwave antigen retrieval with a rabbit polyclonal anti-EP4 antibody (Cayman Chemicals).
Measurement of PGE 2 and VEGF concentrations
Culture medium was collected after incubating cells with fresh medium for 24 h. The concentration of PGE 2 was measured with a PGE 2 ELISA Kit (R&D System, Abingdon, UK) and VEGF with a VEGF ELISA Kit (R&D System) according to the manufacturer's instructions. Each assay was performed in triplicate, and the mean value was expressed as pg/ml.
Cloning of EP4 promoter reporter constructs and CRE reporter luciferase assays Genomic DNA was isolated from C33A cells by digesting them with proteinase K and extracting the digest with phenol. The extracted DNA was used as a template for PCR to clone the EP4 promoter between À2600 and þ82 bp that contains a variant CRE site (CGTCA) at À2528/À2523. The forward primer contained a MluI site at the 5# terminus and had the sequence: 5#-CGACGCGTTGCATTATTTCTCATTCACTTC-3#. The reverse primer contained an XhoI site at the 5# terminus and had the sequence: 5#-CCGCTC-GAGTCCACCCTCTGTACAAACTTT-3#. PCR products were digested with MluI and XhoI and then ligated into pGL2 basic vector (Promega, Madison, WI) to generate EP4-pLuc. The mutant carrying a deletion between À2600 and À2522 of the EP4 promoter was prepared by PCR, using a forward primer 5#-CGACGCGTTAATTAGCTATAACAGAGCAAT-3#.
C33A cells were transfected with EP4-Luc plasmids using Lipofectamine (Invitrogen), and luciferase activity was assayed using the Bioluminescent Reporter Gene Assay System (Tropix, Bedford, MA). At least three independent experiments in duplicate were performed, and promoter activities were normalized to the activity of cotransfected b-galactosidase.
Electrophoretic mobility shift assay using chemiluminescence The binding of CREB to CRE oligonucleotides from EP4 promoter was analyzed by electrophoretic mobility shift assay using the LightShift Chemiluminescent EMSA Kit (Pierce, Chester, UK) as described (11) . The oligonucleotide, which was 5# end labeled with biotin, had the sequence: 5#-TCAAAAAACTCGTCAAATAATTAG-3#.
Statistical analysis
All the experiments were repeated at least three times, and data were presented as means ± standard errors. The non-parametric Mann-Whitney U-test was used to analyze the mean values, and P values ,0.05 were considered statistically significant.
Results
E5 increases the expression of PGE2 receptors, especially the EP4 subtype To examine the effect of the HPV16 E5 protein on the expression of PGE2 receptors, we stably expressed FLAG-tagged E5 protein in C33A human cervical carcinoma cells known to be free of HPV infection. The expression of E5 messenger RNA (mRNA) and protein was confirmed, respectively, by RT-PCR and western blotting using anti-FLAG antibody ( Figure 1A ). Neither E5 mRNA nor protein was detected in the control cells transfected with empty vector. Endogenous expression levels of PGE2 receptors were analyzed in mocktreated or vector-transfected control cells. Among the four subtypes of PGE2 receptors, the mRNA for EP1 and EP4 subtypes showed strong amplification after 30 cycles of RT-PCR, whereas that of EP2 showed strong amplification after 40 cycles ( Figure 1B ). In contrast, EP3 mRNA was not detected even after 40 cycles (data not shown). The stable expression of E5 increased the mRNA levels of EP2 and EP4 but not those of EP1 and EP3, and real-time quantitative RT-PCR analysis revealed an 11.3 ± 5.2-fold increase (P , 0.05) in the EP4 mRNA levels compared with vector-transfected cells ( Figure 1B ). E5 expression also increased the EP4 protein level to 4.9 ± 0.6-fold higher than that in vector-transfected cells (P , 0.05) ( Figure 1B ). Knock down of E5 expression by siRNA in C33A cells reduced EP4 mRNA expression, whereas control siRNA did not reduce it ( Figure 1C ). These results indicate that E5 increases the expression of the EP4 receptor in C33A cervical cancer cells.
EP4 expression is increased in human cervical cancer tissues, and E5 protein increases anchorage-independent colony formation and VEGF expression by activating EP4
To assess the significance of the increase in the EP4 receptor protein in cervical carcinogenesis, the expression of EP4 protein in human cervical cancer tissues was analyzed on tissue arrays by immunohistochemistry. All the normal cervical tissues tested (n 5 4) showed borderline EP4 expression (defined as 'À/þ'). In contrast, most carcinoma tissues showed increased staining intensity: 13 tissues of 52 cervical cancer samples showed strong increases in staining density (þþþ), 29 tissues showed moderate increases (þþ) and 10 tissues showed staining density similar to that of normal tissue (À/þ) ( Figure 2A ). These results suggest an association between increased EP4 expression and cervical carcinogenesis. However, no significant correlation between EP4 expression levels and patient ages or histological types of cancer was observed.
To probe the association in more detail, the effect of EP4 on anchorage-independent colony formation on soft agar and VEGF expression was examined. Expression of E5 increased the colonyforming efficiency to 14.6 ± 1.2% from the value of 8.4 ± 0.8% in vector-transfected cells (P , 0.05), but pretreatment with the EP4 receptor antagonist AH23848 abolished this effect of E5 ( Figure 2B ). The PCR amplification of VEGF mRNA showed two amplification bands that corresponded to VEGF 165 and VEGF 121 (13) . Stable expression of the E5 protein increased the expression of both VEGF mRNA and protein (P , 0.05), which was also blocked by AH23848 treatment ( Figure 2C ). These results suggest that E5 contributes to the cervical carcinogenesis by increasing anchorage-independent colony formation and VEGF expression through activation of EP4 in C33A cervical cells.
E5 induces EP4 expression by activating EGFR and COX-2
To investigate how the E5 protein increases EP4 expression, the role of COX-2 on EP4 expression was examined because COX-2 was suggested to induce EP4. The stable expression of E5 increased the expression of COX-2 mRNA and protein in C33A cells ( Figure 3A) . Treatment of C33A cells expressing E5 with the specific COX-2 inhibitor NS-398 for 24 h reduced the expression of EP4 mRNA and treatment for 48 h completely abolished it ( Figure 3B ). This indicates that E5 may induce EP4 via a mechanism involving COX-2.
Thus, the effect of COX-2 on EP4 expression was therefore analyzed in further detail. Stable COX-2 expression raised EP4 protein expression 2.0 ± 0.4-fold higher than in vector-transfected C33A cells (P , 0.05) ( Figure 3C ). COX-2 also increased the expression of EP4 and EP2 mRNAs. Then, the involvement of EGFR in EP4 induction was examined by treatment with the EGFR inhibitor AG1478. EGFR inhibitor reduced EP4 induction in C33A cells expressing E5 (from 7.6 ± 1.4 to 2.3 ± 0.4, P , 0.05), but not significantly in C33A cells expressing COX-2 (from 6.2 ± 0.7 to 5.8 ± 0.9, P 5 0.41) (supplementary Figure 1 is available at Carcinogenesis Online). To confirm that E5 activates EGFR and induces COX-2, the E5 expression was knock downed with siRNA. Knock down of E5 decreased EGFR phosphorylation and COX-2 induction in C33A cells expressing E5 ( Figure 3D ).
EP4 induction by E5 protein involves PGE2, cAMP, PKA and CREB To explore how COX-2 mediates the induction of EP4 expression by E5, the secretion of PGE2, the major COX-2 product, was analyzed. PGE2 secretion into the medium was higher in cells stably expressing the E5 protein (539 ± 103 pg/ml) and in cells expressing the COX-2 protein (3533 ± 595 pg/ml) than in vector-transfected cells (47.5 ± 14.0 pg/ml protein) (supplementary Figure 2 is available at Carcinogenesis Online). Next, the effect of the increased PGE2 on EP4 expression was examined by treating C33A cells not expressing E5 with PGE2. EP4 mRNA levels began to increase 1 h after treatment with PGE2, they reached a peak at 2 h and then they decreased to baseline at 6 h. The expression of EP4 mRNA at 2 h after PGE2 treatment was 4.5 ± 0.4-fold higher than in the vehicle-treated control (P , 0.05) ( Figure 4A ). PGE2 causes to increase cAMP production, and thus to examine whether PGE2 induces EP4 by increasing cAMP synthesis, the effect of the adenylate cyclase activator forskolin was analyzed. When C33A cells were treated with forskolin, the expression of EP4 mRNA increased in a similar temporal pattern as that observed in PGE2-treated cells ( Figure 4A) . Coincidently, the E5-expressing cells showed higher basal cAMP levels and higher basal levels of CREB phosphorylation than vector-transfected cells ( Figure 4B ). Because cAMP-dependent PKA is the major downstream effector of cAMP, the involvement of PKA in the induction of EP4 by PGE2 was examined. Pretreatment of C33A cells with the PKA inhibitor H-89 decreased PGE2-stimulated EP4 mRNA expression from 4.0 ± 0.3-to 1.6 ± 0.6-fold (P , 0.05) relative to vehicle-treated controls ( Figure 4C) . Next, the involvement of CREB, a major transcription factor target of PKA, in EP4 induction was examined by blocking CREB binding to CRE using CRE-decoy oligonucleotides. Transfection of the CRE-decoy constructs decreased the PGE2-stimulated induction of EP4 mRNA from 4.0 ± 0.3-to 1.5 ± 0.2-fold (P , 0.05) ( Figure  4C ). Because PGE2 has also been reported to activate phosphatidylinositol 3-kinase (PI3K), the involvement of PI3K in EP4 induction was examined. Inhibition of PI3K by treatment with wortmannin also decreased the PGE2-stimulated EP4 induction (P , 0.05, Figure 4C ). This result suggests that EP4 induction by PGE2 in C33A cervical cancer cells involves cAMP, PKA, CREB and PI3K. Therefore, similar experiments were carried out to examine whether the same signaling molecules mediate EP4 induction by E5. Blocking the prostaglandin receptor EP4 or EP2 with specific antagonists or treatment with H-89 and wortmannin inhibited E5-induced EP4 protein expression in cells expressing E5 ( Figure 4D ). This indicates that 
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HPV16 E5 increases EP4 expression in C33A cervical cancer cells through a mechanism involving PGE2, EP2 and EP4, cAMP, PKA, PI3K and CREB.
CRE in the EP4 promoter mediates the induction of EP4 expression by HPV16 E5
Because CREB was found to mediate the induction of EP4 expression by E5, we searched for a CREB-binding site in EP4 promoter region, and we found a variant CRE at position À2528. To study whether this variant CRE mediates EP4 expression induced by E5 protein, we cloned the EP4 promoter containing the CRE into a luciferase reporter plasmid. E5 expression increased EP4 luciferase activity in C33A cells to 2.0 ± 0.2-fold higher levels than in the vector-transfected cells (P , 0.05), whereas deleting the CRE decreased the luciferase activity to 0.8 ± 0.1-fold (P , 0.05) ( Figure 5A ). This indicates that the variant CRE mediates EP4 induction by E5. To confirm the signaling pathway mediating EP4 transcription induced by E5, we assessed the luciferase activity in vector-transfected cells. Treatment of C33A cells with forskolin and PGE2 increased luciferase activity to levels 1.8 ± 0.2-fold (P , 0.05) and 1.7 ± 0.1-fold (P , 0.05) higher than that of vehicle-treated control, respectively ( Figure 5B ). Treating E5-expressing C33A cells with NS-398, AH6809, AH23848, H89, wortmannin and CRE-decoy decreased luciferase activity to 0.9 ± 0.3-, 0.8 ± 0.2-, 0.9 ± 0.2-, 0.5 ± 0.0-, 0.8 ± 0.1-and 0.5 ± 0.1-fold, respectively, from the 2.0 ± 0.2-fold induction seen in the E5-expressing control (P , 0.05, Figure 5B ). These results suggest that PGE2, EP2 and EP4, cAMP, PKA and PI3K mediate the transcription of the EP4 gene induced by E5 in C33A cells.
To confirm that CREB binding to the variant CRE site in the EP4 promoter mediates EP4 expression, the binding of CREB to CRE oligonucleotides derived from the EP4 promoter was analyzed by electrophoretic mobility shift assay. Expression of E5 protein increased CREB binding to a level 3.2 ± 0.1-fold (P , 0.05) higher than the level seen in vector-transfected cells ( Figure 5C ). Treatment of E5-expressing cells with forskolin further increased CREB binding (6.1 ± 0.4-fold, P , 0.05), whereas treatment with NS-398, H89 and wortmannin decreased CREB binding to, respectively, 1.3 ± 0.0-, 1.6 ± 0.1-and 1.4 ± 0.1-fold (P , 0.05) the level seen in control cells. Treatment with the PGE2 receptor antagonists AH6809 or AH23848 also decreased CREB binding to CRE. These results indicate that COX-2, PGE2, EP2, EP4, cAMP, PKA, PI3K and CREB mediate the EP4 expression induced by E5 by increasing CREB binding to the variant CRE in the EP4 promoter in C33A cervical cancer cells.
E5 protein induces EP4 expression in other cervical cancer cells
Given the above results that E5 induces EP4 expression in C33A cervical cancer cells through a mechanism involving EGFR, COX2, PGE2, EP2 and EP4, cAMP, PKA, PI3K, CREB and CRE, experiments were conducted to ask whether the EP4 induction by E5 is common to other cervical cancer cells. HeLa human cervical cancer cells, which are HPV18 positive and express high levels of COX-2, were used for additional analysis. Similar to C33A cells, treatment of HeLa cells with AG1478, NS-398, AH23848, H89, wortmannin and CRE-decoy decreased EP4 expression to, respectively, 0.4 ± 0.1-, 0.3 ± 0.1-, 0.2 ± 0.1-, 0.5 ± 0.1-, 0.6 ± 0.1-and 0.5 ± 0.1-fold (P , 0.05) the levels seen in HeLa control cells ( Figure 6A ). In addition, CaSki cells, which are HPV16-positive cervical cancer cells expressing E5 (14) , were treated with E5 siRNA. Knock down of E5 in CaSki cells also resulted in a decreased EGFR phosphorylation, COX-2 expression and EP4 induction ( Figure 6B ). These results indicate that E5 induces EP4 expression via COX2, EP2 and EP4, PKA, PI3K and CREB in HeLa cells and CaSki cells as well as in C33A cells, suggesting that HPV16 E5 induce EP4 expression via similar prostaglandin pathways in other cervical cancer cells.
Discussion
This study investigated the oncogenic mechanism of the HPV E5 protein by addressing whether the HPV16 E5 protein can stimulate PGE2-signaling pathways that are implicated in cervical carcinogenesis. The experiments also sought to investigate the mechanism whereby this stimulation occurs. This study showed that E5 induces expression of the PGE2 receptor subtype EP4 in various cervical carcinoma cells, through a mechanism sequentially involving EGFR, COX-2, PGE2, EP2 and EP4, PKA, CREB and CRE.
The present findings indicate that the HPV16 E5 protein may exert its oncogenic effect at least partly by inducing the expression of the EP4 prostanoid receptor. EP4 activates stimulatory G proteins to increase the formation of cAMP following binding with PGE2. The increase in cAMP levels activates PKA, which phosphorylates various target molecules such as CREB. The phosphorylated CREB binds to CRE to turn on the transcription of $4000 target genes, including various cancer-related genes (15, 16) . Thus, the induction of PGE2 and EP4 by E5 protein results in continuous activation of cAMP-signaling pathways, which may facilitate cervical carcinogenesis. The involvement of EP4 in cervical oncogenesis was suggested by the increased level of EP4 mRNA in cervical cancers (8) . The present study demonstrates an increase in EP4 protein expression in cervical cancer tissues by immunohistochemical analysis of 52 cancer tissues, which supports a strong association of E5 protein with cervical carcinogenesis. This study provides further evidence for EP4 involvement in cervical carcinogenesis by showing that EP4 mediates the E5-induced increase in colony-forming efficiency and in VEGF C33A cells stably expressing E5 were treated with 30 lM NS-398 for 48 h, and then EP4 mRNA expression was analyzed by RT-PCR. C refers to the E5-expressing C33A cell control treated with vehicle. (C) Overexpression of COX-2 increased EP4 expression in cervical cancer cells. C33A cervical cancer cells stably expressing COX-2 were established by transfection with COX-2-pcDNA3 plasmid, and expression of COX-2 was confirmed by RT-PCR and western blotting. Expression of EP receptors in the COX-2-expressing cells was assessed by RT-PCR, and expression of EP4 protein was analyzed by western blotting. COX#1 and COX#7 refer to the COX-2-expressing C33A cell clones. Asterisks indicate significant differences from the vector-transfected or vehicle-treated controls (P , 0.05, Mann-Whitney U-test). (D) Knock down of E5 blocked the EGFR phosphorylation in C33A cells. After 48 h after transfection of 100 nM E5 siRNA, EGFR phosphorylation was analyzed by western blotting using antibody specific for EGFR phosphorylated on Tyr-845. The expression of E5, COX-2 and EP4 mRNA was analyzed by RT-PCR using specific primers. C refers to the transfection of control siRNA.
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secretion in cervical cancer cells, both of which are required for tumor growth, angiogenesis and metastasis (17) . Though a few studies have reported on the role of EP4 in cervical carcinogenesis, many studies focus on the role of EP4 in the carcinogenesis, progression, metastasis, treatment and prevention of other types of cancer, including colon cancer (18) and breast cancer (19) . Together with these reports, the present study suggests that HPV E5 may play an important role in the carcinogenesis, progression and metastasis of cervical cancer by inducing EP4 and that targeting EP4 may be useful for preventing and treating cervical cancer since the selective targeting of individual EP receptors may prove more effective than targeting COX-2 in cancer treatment (20, 21) . In addition, E5 was also reported to activate endothelin-1 receptor, another G protein-coupled receptor to stimulate growth of keratinocytes, which might contribute to oncogenesis (22) . However, E5 protein was believed to contribute to early stage of cervical carcinogenesis or acute stage of papilloma formation because the open reading frame of E5 gene was found to be often deleted when HPV DNA is integrated into host genome (23, 24) . Nevertheless, E5 gene was expressed in many cervical cancer tissues without integration to host cell genome. E5 transcript was detected in approximately half of the tissues from carcinoma in situ and cervical cancer, and most of the E5 transcript was from episomal HPV (25, 26) , supporting some roles of E5 protein in the late stages cervical carcinogenesis.
In this study, we showed that HPV16 E5 induces EP4 expression in C33A cervical cancer cells via sequential involvement of EGFR, COX-2, PGE2, EP2 and EP4, PKA, CREB and CRE ( Figure 6C ). The induction of EP4 by COX-2 is supported by previous reports demonstrating that COX-2 colocalizes with EP4 in the vasculature of human kidney (27) and that the EP4 expression is decreased in the skin of COX-2À/À mice (28) . Furthermore, PGE2 was found to induce EP4 expression in cervical cancer cells by a mechanism dependent on EP2 and EP4, and similar EP4 induction by PGE2 has been reported in ovarian cancer cells (29) . EGFR activation was found to be required in the EP4 expression induced by E5, but not in the induction of EP4 expression by COX-2, suggesting that the induction of COX-2 by E5 requires EGFR activation, which coincides with the report that EGFR mediates COX-2 expression induced by HPV16 E6 and E7 in cervical cancer cells (30) . These results lead to the conclusion that E5 may activate the EGFR to induce COX-2 expression, which increases the synthesis and secretion of PGE2. The secreted PGE2, in turn, binds and activates EP2 and EP4 in an autocrine/paracrine manner to induce EP4 expression. Thus, E5 as well as E6 and E7 is suggested to induce EP4 via COX-2 expression, so further studies are needed to investigate the respective contribution and significance of EP4 induction by E5, E6 and E7 protein in cervical carcinogenesis.
Though PGE2 has been reported to induce EP4 expression, the mechanism by which this occurs remains unknown. Studies in nonsmall cell lung cancer cells have shown that extracellular signalregulated kinase, PI3K, CCAAT/enhancer-binding protein and transcription factor AP-2 are involved in the EP4 expression (31, 32 ). The present study shows for the first time, to the best of our knowledge, that PGE2 induces EP4 expression by stimulating the binding of CREB to a variant CRE site in the promoter of the human EP4 gene. Two classes of CRE have been reported: a consensus palindrome (TGACGTCA) with high affinity to the CREB and variant CREs containing only a half-site TGACG sequence with the reduced affinity (33). Because we found that a CRE-decoy inhibited EP4 induction, we analyzed the promoter region of the human EP4 gene (GenBank accession number: NM 000958) and identified a variant CRE site (CGTCA) at À2528/À2523, though there was no CRE consensus palindrome (34, 35) . Using a luciferase reporter assay and electrophoretic mobility shift assay, we confirmed that this variant CRE mediates the EP4 expression induced by E5 and PGE2, and the induction was dependent on COX-2, EP2 and EP4, cAMP, PI3K, PKA and CREB.
The present study presents a novel example of positive feedback regulation of the prostaglandin signaling system that amplifies the cellular responses (36) (37) (38) . The E5 protein induces COX-2, which increases synthesis and secretion of PGE2. Secreted PGE2 induces EP4 via cAMP-signaling pathways. Then, the increased EP4 protein results in further amplification of the cellular response to PGE2. Moreover, an increase in the cAMP-signaling pathway has been reported to upregulate COX-2 expression by increasing CRE-dependent transcription (38) , stabilizing COX-2 mRNA and stimulating translation (39) . In addition, EP4 receptor stimulation can activate PI3K to stimulate T-cell factor-dependent transcriptional activity (40) , which upregulates COX-2 transcription (41) .
From this study, we conclude that HPV E5 protein induces expression of the EP4 subtype of the PGE2 receptor in cervical cancer cells, and this induction involves a variant CRE of EP4 promoter. This finding suggests that E5 plays an oncogenic role partly through upregulating the expression of the EP4 receptor, implying that HPV16 E5 may be a useful target for preventing carcinogenesis and progression of cervical cancer. Supplementary Figures 1 and 2 can be found at http://carcin. oxfordjournals.org/ 5 . A variant CRE in the EP4 promoter mediates HPV16 E5-induced EP4 expression. (A) Induction of EP4 expression by HPV16 E5 was mediated by a variant CRE site in the EP4 promoter. The region of the human EP4 promoter containing a variant CRE was cloned to generate the EP4-Luc reporter construct, and C33A cells were transfected with 0.2 lg of wild-type EP4-Luc plasmid or a mutant plasmid in which the CRE was deleted, together with 0.2 lg of a b-galactosidase expression plasmid. After 48 h, luciferase activity was measured and normalized to b-galactosidase activity. WT refers to a luciferase reporter construct containing wild-type EP4 promoter, D refers to a construct containing CRE site-deleted EP4 promoter. (B) EP4 promoter activity was regulated by the cAMP signaling system. At 24 h after transfection with the wild-type EP4-Luc plasmid, cells were treated with forskolin (20 lM), H89 (10 lM), wortmannin (100 nM), NS-398 (30 lM), AH6809 (10 lM) or AH23848 (10 lM). After drug treatment for 24 h, luciferase activity was measured. The CRE-decoy (200 nM) was cotransfected with the EP4-Luc, and luciferase activity was measured after 48 h. (C) Binding of CREB to CRE in the EP4 promoter was mediated by the prostaglandin signaling system. E5-expressing C33A cells were treated with 20 lM forskolin, 10 lM H89, 100 nM wortmannin, 30 lM NS-398, 10 lM AH6809, 10 lM AH23848 or vehicle (V) for 24 h. Then, the binding of CREB to CRE in the EP4 promoter was analyzed by electrophoretic mobility shift assay using a chemiluminescent, biotin-labeled DNA probe. For a competition assay, a 100-fold molar excess of cold CRE oligonucleotide was added to the binding reaction. Asterisks indicate significant differences from the vehicle-treated control cells (P , 0.05, Mann-Whitney U-test).
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